• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Tosulfloxacin versus norfloxacin for prevention of infections in chemotherapy-induced neutropenic patients.

作者信息

Mori S, Ohashi K, Akiyama H, Shoji H, Sato H, Tanikawa S, Sakamaki H, Onozawa Y

机构信息

Hematology Division, Tokyo Metropolitan Komagome Hospital.

出版信息

Kansenshogaku Zasshi. 1994 Jul;68(7):872-8. doi: 10.11150/kansenshogakuzasshi1970.68.872.

DOI:10.11150/kansenshogakuzasshi1970.68.872
PMID:8089554
Abstract

We conducted a non-randomized, prospective study comparing the efficacy of tosulfloxacin with that of norfloxacin in preventing bacterial infection during chemotherapy-induced neutropenic episode. Fifty-one patients with hematological malignancies were included, and a total of 108 episodes of neutropenia were studied. There was no significant difference between the two groups in the incidence of fever, in the time-to-event analysis of febrile episodes nor in the incidence of gram-positive bacteremia despite the broader spectrum of tosulfloxacin. The incidence of gram-negative bacteremia was lower in patients treated with the quinolones as a prophylactic than in the historical controls given polymyxin B. Especially the incidence of bacteremia due to Pseudomonas aeruginosa was significantly less when tosulfloxacin was used. A possible synergistic effect of sulfamethoxazole-trimethoprim in preventing the febrile episode was also observed.

摘要

相似文献

1
Tosulfloxacin versus norfloxacin for prevention of infections in chemotherapy-induced neutropenic patients.
Kansenshogaku Zasshi. 1994 Jul;68(7):872-8. doi: 10.11150/kansenshogakuzasshi1970.68.872.
2
Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.血液系统恶性肿瘤和严重中性粒细胞减少患者停用诺氟沙星预防用药的效果。一项关于对感染性发病率影响的配对病例对照研究。
Acta Haematol. 1998;99(4):206-11. doi: 10.1159/000040840.
3
Prophylactic co-trimoxazole versus norfloxacin in neutropenic children--perspective randomized study.中性粒细胞减少儿童预防性使用复方新诺明与诺氟沙星的前瞻性随机研究
Infection. 1989 Mar-Apr;17(2):65-9. doi: 10.1007/BF01646878.
4
[Prophylaxis with fluoroquinolones in patients with neutropenia].中性粒细胞减少症患者使用氟喹诺酮类药物进行预防
Medicina (B Aires). 1993;53(5):401-7.
5
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group.中性粒细胞减少患者基于喹诺酮的抗菌化学预防:增强革兰氏阳性菌活性对感染发病率的影响。加拿大国立癌症研究所临床试验组
Ann Intern Med. 1996 Aug 1;125(3):183-90. doi: 10.7326/0003-4819-125-3-199608010-00004.
6
Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.血液系统恶性肿瘤中性粒细胞减少患者细菌感染的预防。一项比较诺氟沙星与环丙沙星的随机、多中心试验。GIMEMA感染项目。意大利成人恶性血液病研究组。
Ann Intern Med. 1991 Jul 1;115(1):7-12.
7
Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients.
Drugs Exp Clin Res. 1992;18(4):141-6.
8
The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients.用于中性粒细胞减少的癌症患者抗菌预防的新型氟喹诺酮类药物。
Eur J Cancer. 1993;29A Suppl 1:S2-6. doi: 10.1016/s0959-8049(05)80252-7.
9
Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis.
Am J Med. 1988 May;84(5):847-54. doi: 10.1016/0002-9343(88)90062-9.
10
Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
J Antimicrob Chemother. 1994 Apr;33(4):837-44. doi: 10.1093/jac/33.4.837.